Fem-årige tilbud på peptidforsyninger: Lektioner fra Amylyx og Bachem

Piller 1: Kvantificer din efterspørgselsusikkerhed, før du forpligter dig

Den mest almindelige fejl i langsigtede peptidforsyningsaftaler er bindende volumenforpligtelser til en efterspørgselsprognose, der ikke er stresstestet i forhold til programmets faktiske kliniske og regulatoriske usikkerhed.

Amylyx-Bachem-aftalen udskyder minimumskøbsforpligtelser til 2028 — mindst to år efter underskrivelsen. Den kløft er ikke generøsitet; det er en erkendelse af, at avexitides kommercielle mængder afhænger af FDA-godkendelsestimingen, mærkets omfang, og beslutninger om betaleradgang, der forbliver uafklarede ved kontraktudførelse. Strukturen adskiller kapacitetsreservation (hvilket kan gøres tidligt) fra volumenforpligtelse (som først begynder, når efterspørgselskonvolutten bliver mere håndterbar).

Før du accepterer en minimumsmængde årligt (MAG) klausul, køre tre scenarier på tværs af din prognosemodel:

• Bundkasse: godkendelse i forventet vindue, etiket matcher målindikation

• Forsinkelsessag: tolv-til-atten måneders godkendelsesforsinkelse, ingen indflydelse på indikationens omfang

• Downside sag: smal etiketgodkendelse, begrænset markedsadgang, eller nedprioritering af pipeline

Hvis MAQ overstiger din downside-case volumen med mere end 20-25 %, du køber reelt en forsikring for et kapacitetsniveau, du måske aldrig har brug for - og betaler take-or-pay-bøder, når du ikke kan absorbere det. Forhandle nedtrapningsbestemmelser, der tillader volumenreduktioner som reaktion på dokumenterede regulatoriske eller kommercielle udløsere. Standardsproget fra SEC-arkiverede API-forsyningsaftaler giver sponsorer mulighed for at påberåbe sig force majeure eller væsentlige negative ændringer, men disse retsmidler er vanskelige at påberåbe sig og uvægerligt anfægtede; en forud forhandlet nedtrapningsmekanisme er langt mere operationelt nyttig.

⚠️ Fejltilstand: Underskriver en flad MAQ, der er bundet til base-case lanceringsantagelser, derefter absorbere take-or-pay gebyrer på 20-40 % af uordnet volumen, når en forsinket godkendelse eller begrænset etiket komprimerer kommerciel optagelse under prognosen.

Piller 2: Forstå, hvad du faktisk betaler for i reservationsøkonomi

Polypeptidgruppens termark inkluderede en $30 million forudgående kapacitetsreservationsgebyr - et tal, der er stort nok i absolutte tal til at foretage en betydelig kontrol på bestyrelsesniveau, men som afspejler en stadig mere normal omkostningsstruktur for GMP-peptidproduktionskapacitet i stor skala.

Reservationsøkonomi i peptid-CDMO-aftaler inkluderer nu typisk to forskellige finansielle instrumenter, der ofte sammenblandes:

1. Kapacitetsreservationsgebyr (CRF): en fast betaling, ofte ikke refunderes eller kun delvist krediteres mod fremtidige købsfakturaer, der sikrer navngivne produktionsslots for et defineret peptid, renhedsspecifikation, batch størrelse, og udgivelsesstandard. Gebyret kompenserer CDMO for at holde kapacitet mod en fast forpligtelse i stedet for at fylde den opportunistisk med andre kunders kampagner.

2. Vedligeholdelsesgebyrer: tilbagevendende betalinger, der dækker kvalitetsovervågning, lovpligtig filvedligeholdelse, metodefastholdelse, og periodiske kampagneforberedende aktiviteter i perioder med lav eller ingen aktiv produktion - hvad Amylyx-Bachem-afsløringen omtaler som "vedligeholdelsesgebyrer og -udgifter."

Sondringen har betydning for finansiel modellering. En CRF er en sunk kapitalomkostning bundet til optionens værdi; vedligeholdelsesgebyrer er tilbagevendende driftsomkostninger, der fortsætter selv i år, hvor der ikke forekommer produktionskørsler. Begge skal fremgå af nettonutidsomkostningsberegningen over aftaleperioden.

Før underskrift, uddrage svar på fire spørgsmål fra aftaleudkastet:

1. Er CRF fuldt kreditværdig, delvis kreditværdig, eller fortabes ved aflysning?

2. Under hvilke betingelser konverteres CRF til en eksigibel forpligtelse (dvs., when does the option become a liability)?

3. What triggers a maintenance fee invoice, and what is the audit right attached to it?

4. If the primary site cannot fulfill a reserved slot, does the CDMO have an obligation to provide an equivalent slot at an alternate qualified facility — and within what timeline?

The third question is frequently underdefined in first-draft agreements. Tier-1 CDMOs operating at scale commonly include language allowing unilateral rescheduling of reserved slots within a defined window, sometimes as short as thirty days, with no monetary remedy to the sponsor. Negotiate explicit remedies — accelerated delivery rights, priority rebooking within a defined period, or fee credits — before the agreement is executed.

Peptidsyntese Om current CDMO pricing analysis, Tier-1 CDMOs now routinely require 10–20% advance reservation deposits for research-scale agreements and 40–50% upfront non-refundable commitments for commercial-scale capacity. Understanding where your deal sits in that range — and why — is a foundational negotiation input.

Piller 3: Kort teknisk-overførselsberedskab, før du låser en partner

A supply agreement binds you commercially to a specific CDMO partner. Technical transfer complexity determines how easily you can exit that binding if circumstances change — and how much switching costs will constrain your negotiating leverage on renewals.

Peptide Contract Manufacturing Pricing Trends Q2 2026 places technology transfer costs for complex peptide APIs at $300,000–$800,000 or more, depending on process complexity, analytical method portfolio size, and GMP documentation burden. That range creates significant lock-in for programs with difficult sequences, multi-step modifications, or extensive stability-indicating method sets. The higher your transfer cost, the more leverage your CDMO has at renewal — and the more important it is to build transfer readiness into the original agreement.

Technical transfer readiness is best evaluated across four dimensions before signing:

An agreement that does not address method transfer protocol ownership, DMF filing rights, or post-agreement analytical record retention is one that hands the CDMO de facto veto power over any future transition. Negotiate:

• Sponsor access to batch records and analytical data within a defined period of request

• A right to conduct technical transfer to a qualified secondary or Syntetiske peptider tertiary site during the agreement term (not only at termination)

• Specific timelines and cost-sharing provisions for any required re-validation at a new site

De EMA Guideline on the Development and Manufacture of Synthetic Peptides provides the regulatory baseline for what analytical controls must be in place for GMP-grade synthetic peptide APIs. Your transfer readiness assessment should verify that the CDMO’s current control strategy satisfies this standard — not merely that they assert it does.

Til tip: Request a “transfer readiness simulation” as part of final due diligence: ask the CDMO to provide the batch record index, method list, and DMF chapter inventory they would need to transfer to demonstrate readiness. Gaps in that inventory are negotiation leverage before signing — they become contractual disputes after.

Piller 4: Indbygg Contingency Sourcing i aftalearkitekturen, Ikke som en eftertanke

The Amylyx-Bachem agreement is explicitly non-exclusive: Bachem is one of two simultaneously engaged CDMOs, with Polypeptide Group holding a parallel supply commitment. This structural choice reflects a clear risk management posture — single-source dependence for a commercial peptide API is no longer considered acceptable practice by biopharma legal and supply chain teams who have experienced the post-2020 supply disruption environment.

Dual-sourcing for peptide APIs is not simply about having a backup vendor on file. A backup vendor that has not completed analytical comparability, process qualification, or regulatory file alignment is operationally unavailable when you need it. The operational standard, validated by building a resilient peptide supply chain, is a staggered second-source protocol:

Fase 1 (Months 1–3): Desk audit and analytical method transfer to secondary vendor. CoA comparability study using split-lot samples. No active manufacturing commitment.

Fase 2 (Months 4–9): Pilot comparability batches at secondary site. Analytical equivalence assessment for identity (ESI-MS eller MALDI-TOF), renhed (RP-HPLC), and impurity profiles. Regulatory file alignment.

Fase 3 (Ongoing): Standing bridge allocation of 10–20% of routine purchase volume to secondary vendor. This maintains the secondary site’s production continuity and team familiarity with the process without incurring full commercial duplication costs.

The contingency sourcing provision in the primary supply agreement should explicitly address:

• The sponsor’s right to qualify and activate a secondary source during the agreement term, without triggering a breach-of-exclusivity claim (particularly if the primary agreement contains any preferred-supplier language)

• Defined escalation triggers that convert the secondary vendor from standby to primary allocation — delivery SLA failures, batch release failures above a defined frequency threshold, regulatory action, or material financial distress

• Supplier switching timeline commitments: what is the maximum number of days from trigger activation to first commercial batch delivery from the secondary source?

Per the dual-sourcing strategy guidance for biopharma, -en 70/30 eller 60/40 commercial split across primary and secondary CDMOs is an operational benchmark that maintains secondary-source readiness without imposing equivalent cost to full parallel manufacturing.

⚠️ Fejltilstand: Qualifying a secondary CDMO on paper but not in practice — no pilot batches completed, no analytical comparability data on file, no regulatory filing amendments to add the alternate site. When the primary site has a capacity shortfall or quality excursion, the backup cannot legally supply commercial-grade material.

Piller 5: Definer ansvar for frigivelsestest med kontraktlig præcision

Release testing responsibility is the most commonly under-specified element in peptide API supply agreements, and the most consequential when a batch fails or a specification dispute arises.

The Amylyx-Bachem agreement allocates testing and supply responsibilities to Bachem as the manufacturer, with Amylyx retaining product specification authority and final lot disposition rights as the sponsor/applicant. This is the standard architecture under ICH Q7 and standard industry quality agreements — but the details within that architecture matter enormously.

For a GMP synthetic peptide API, minimum release specifications require orthogonal analytical coverage per regulatory guidance. Ifølge PolypPeptide’s CMC quality control white paper, lot release specifications must be sufficient to establish identity, renhed, styrke, and where applicable, safety (endotoksin, sterilitet) of the peptide API. A practical minimum release panel includes:

Beyond the panel itself, the quality agreement attached to the supply agreement must clearly assign responsibility for:

• Testing authority: who performs each test, and at which site (CDMO QC, sponsor QC, or independent third-party laboratory)?

• OOS investigation ownership: when a result falls outside specification, who initiates the investigation, what is the timeline, and what authority does the CDMO have to release a lot pending investigation resolution?

• Lot disposition authority: the CDMO typically performs provisional internal QC disposition; the sponsor retains final release authority for GMP lots intended for clinical or commercial use

• CoA format and data retention: the CoA must include batch number, all test results with raw data references (kromatogrammer, spektre), analyst ID, og udgivelsesdato. Data retention obligations and sponsor access rights should be defined contractually, not left to the CDMO’s internal SOPs

This distribution of testing and disposition authority is the contractual backbone of your lot-level risk management. When a batch fails, ambiguity about who owns the investigation or the release decision translates directly to timeline risk and regulatory exposure.

Anvendelse af rammen: En forhåndssignatur-tjekliste

The five pillars above convert to a structured pre-signature review that can be completed across a standard legal and technical due diligence cycle. For each pillar, the minimum acceptance condition is:

Any cell left blank or answered with “to be defined” before signing is a gap that will need to be resolved — under worse conditions — after execution.

Samarbejde med din CDMO-partner om aftalevilkår

The framework above is an evaluation and negotiation tool, not a prescriptive contract template. Real supply agreement negotiations involve counterpart constraints, market capacity realities, and relationship context that generic checklists cannot capture. The most productive outcome of applying this framework is a structured conversation with your CDMO counterpart about which provisions are standard, which are negotiable, and which require creative structural solutions.

For biopharma development teams building peptide programs from the milligram-to-kilogram scale, having a CDMO partner with explicit expertise in technical transfer, analytical method development, and quality agreement architecture reduces the friction in each of these five areas. MOL ændringer supports peptide synthesis programs across the full development continuum — from complex custom sequences requiring 300+ functional group modifications to GMP-compatible production in Class 100 cleanroom environments with full HPLC, MS, and endotoxin QC — and can provide a technical feasibility assessment to help teams understand their specific agreement risk profile before negotiations begin.

The Amylyx-Bachem agreement, read at the level of its contractual mechanics rather than its headline announcement, is a useful reference point. Every team entering a multi-year peptide supply commitment should be able to account for each of the five pillars described above — not because the deal terms are identical to Amylyx’s, but because the categories of risk are.

Reviewed by the MOL Changes Peptide Science Team. MOL Changes is a commercial-stage peptide synthesis and CDMO services provider; the framework in this article reflects industry-standard practice and publicly available regulatory guidance, not proprietary claims.